125683 (Tested • BREAKDOWN)

As of April 2026, here is an informative review of the clinical and regulatory findings associated with this product, specifically focusing on the data submitted under regarding infusion rate increases. Clinical Review of Xembify (STN: 125683)

: Pharmacokinetic (PK) data supported the safety of these changes, confirming that the drug's effectiveness in maintaining protective IgG levels remains consistent even with faster administration. Summary of Benefits vs. Risks Clinical Observation Primary Indication Treatment of Primary Immunodeficiency (PI). Key Advantage 125683

: This increase allows for significantly shorter infusion times, which is a major factor in treatment adherence and quality of life for patients requiring long-term immune globulin replacement therapy. As of April 2026, here is an informative

High concentration (20%) allows for lower infusion volumes and faster delivery. Generally well-tolerated at rates up to 35 mL/hour/site. Primary Risks Generally well-tolerated at rates up to 35 mL/hour/site

Xembify is indicated for the treatment of in patients aged 2 years and older. Recent clinical reviews by the FDA have focused on Supplemental Biologics License Applications (sBLA) to increase the maximum allowable infusion rates. Efficacy and Tolerability